2012

Kereiakes DJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Popma JJ, Stone GW, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD. Longitudinal stent deformation: Quantitativ coronary angiogrphic analyis from the PERSEUS WH and PLATINUM WH randomized conrolle clinical trials. J Am Coll Cardiol 2012;59:E320; e-Abstract 2506-7; oral presentation ACC 2012 3/26/12, Chicago, IL.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA. A randomized, double-blind, placebo-controlled trial of the safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin Type 9 serine protease, REGN727/SAR236553, in patients with primary hypercholesterolemia. ACC 2012 LBCT; oral presentation ACC 2012 3/26/12, Chicago, IL.

Kedhi E, Stone GW, Kereiakes DJ, Serruys P, Parise H, Fahy M, Simonton CA, Sudhir K, Sood P, Smits P. Stent thrombosis: Insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trial. J Am Coll Cardiol 2012;59:E321; e-Abstract 2506-9; oral presentation ACC 2012 3/25/12, Chicago, IL.

Oparil S, Izzo JL, Chrysant SG, Kereiakes DJ, Melino M, Lee J, Fernandez V, Heyrman R. Efficacy and safety of olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in male/female participants with severe hypertension: the TRINITY study. ESH 2012; OP.8A.06 (abstract); presented 4/29/12 ESH 2012.

Chrysant SG, Oparil S, Izzo JL, Kereiakes DJ, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in participants with diabetes and severe hypertension. ASH 2012 (PO-196; poster presentation). Journal of Clinical Hypertension 2012;14(suppl 1):A101-102.

Roth EM, Oparil S, Kereiakes DJ, Izzo JL, Chrysant SG, Melino M, Lee J, Fernandez V, Heyrman R. TRINITY: Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in obese participants with severe hypertension. ASH 2012 (PO-208; poster presentation). Journal of Clinical Hypertension 2012;14(suppl 1):A106.

Izzo JL, Kereiakes DJ, Chrysant SG, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. TRINITY: Long-term efficacy and safety of olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide by ethnicity. ASH 2012 (PO-200; poster presentation). Journal of Clinical Hypertension 2012;14(suppl 1):A103.

Lewin AJ, Izzo JL, Oparil S, Chrysant SG, Kereiakes DJ, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in elderly participants with severe hypertension. ASH 2012 (PO-205; poster presentation). Journal of Clinical Hypertension 2012;14(suppl 1):A105.

Cannon LA, Kansal AR, Stern S, Kereiakes DJ, Amorosi SL, Underwood PL, Dawkins KD. Economic modeling of cost-effectiveness for TAXUS Element (ION) versus TAXUS Liberté drug-eluting stents. CRT 2012 (ABS264; poster presentation, Washington, DC).

Meredith I, Teirstein P, Stone G, Mann T, Rabinowitz A, Lee TC, Kereiakes DJ, Allocco D, Dawkins K. The PLATINUM small vessel trial: evaluation of the novel thin-strut platinum-chromium PROMUS Element small vessel everolimus-eluting stent. EuroPCR 2012 (Eurointervention 2012;7:Supplement M).

Stolen CM, Thackeray LM, Chung ES. Relationship between lead location and left ventricular remodeling with peri-infarc pacing. Scientific Sessions of the International Society for Heart and Lung Transplantation, Prague, Czech Republic. April 2012.

Chung ES, Erickson M, Torres V, Haas G, Magalski A, Adamson P, Costanzo MR, Murillo J. Monitoring of respiratory rate derived from an implantable right ventricular pressure sensor in patients with heart failure. Scientific Sessions of the International Society for Heart and Lung Transplantation, Prague, Czech Republic. April 2012.

Chung ES, Erickson M, Torres V, Haas G, Magalski A, Adamson P, Costanzo MR, Murillo J. Monitoring of respiratory rate derivd from an implantable right ventricular pressure sensor in patients with heart failure. Scientific Sessions of the Heart Rhythm Society, Boston, MA, May 2012.

Miszalski-Jamka K, Taylor M, Glowacki J, Hor KN, Miszalski-Jamka T, Rycaj J, Adamczyk T, Kwiecinski R, Klys J, Williams KI, Huang VM, Kluczewska E, Kalarus Z, Mazur W. Left ventricular twists abnormalities in patients with left ventricular non-compaction. A cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2012 Feb 1;14 Suppl 1:P143.

Tipton AL, Hor KN, Mazur W, Collins D, King-Strunk M, Gottliebson W, Taylor M. Cardiac magnetic resonance characteristics of pediatric Cardiac Teratoma. J Cardiovasc Magn Reson. 2012 Feb 1;14 Suppl 1:T2.

Hor KN, Cripe L, Madueme P, Ryan TD, Mazur W, Al-Khalidi H, Raman SV, Sticka J, Jefferies JL, Benson DW, Taylor M. Presence of late gadolinium enhancement in Duchenne muscular dystrophy patients is associated with age and global ventricular function. J Cardiovasc Magn Reson. 2012 Feb 1;14 Suppl 1:P193.

Tipton AL, Gottliebson W, Hor KN, Germann J, Mazur W, Benson WD, Taylor M. Modified short axis geometry for left ventricular assessment in patients with hemodynamically significant pulmonary regurgitation. J Cardiovasc Magn Reson. 2012 Feb 1;14 Suppl 1:T1.

Madueme P, Hor KN, Germann J, Mazur W, Jefferies JL, Taylor M. Comparison of area-length method by echocardiography versus full volume quantification by cardiac magnetic resonance imaging for the assessment of left atrial volume. J Cardiovasc Magn Reson. 2012 Feb 1;14 Suppl 1:P297.

Miszalski-Jamka K, Blelka A, Glowacki J, Klys J, Miszalski-Jamka T, Kwiecinski R, Szulik M, Markowicz-Pawlus E, Mazur W, Kukulski T, Kalarus Z, Silesian Center for Heart Disease, Zabrze, Poland. The rationale for different cut-off values of non-compacted to compacted ratio in the diagnosis of left ventricular non compaction. Presented March 24, 2012 at the ACC 2012, Chicago, IL.

Miszalski-Jamka K, Blelka A, Glowacki J, Klys J, Miszalski-Jamka T, Kwiecinski R, Mazur W, Kukulski T, Kalarus Z. Differently calculated non-compacted ratios cannot be used interchangeably for left ventricular non-compations diagnosis. Presented at EuroCMR, Vienna, Austria, May 17-19, 2012.

2011

Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Serruys PW, Stone GW. Comparison of the everolimus-eluting and paclitaxel-eluting stents in patients with acute and stable coronary syndromes:  Results from the SPIRIT II, III IV and COMPARE trials. J Am Coll Cardiol 2011;57:E902.

Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, Stone GW. Percutaneous revascularization in multivessel coronary disease is improved with everolimus-eluting stent deployment: Pooled analysis from the SPIRIT II, III, IV, and COMPARE trials. J Am Coll Cardiol 2011;57:E1643.

Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, Stone GW. Multivariable predictors of clinical restenosis, cardiac death or myocardial infarction to 2 years following everolimus or paclitaxel drug-eluting stent deployment: The SPIRIT II, III, IV and  COMPARE trial experience. J Am J Cardiol 2011;57:E1622.

Claessen B, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Serruys PW, Stone GW. Two-year outcomes with everolimus-eluting stents vs. paclitaxel-eluting stents according to lesion length and vessel diameter: Pooled analysis from the  SPIRIT II, III, IV and COMPARE randomized trials. J Am Coll Cardiol 2011;57:E1697.

Kereiakes DJ, Cannon LA, Ormiston JA, Turco MA, Wang H, Underwood P, Dawkins KD. Propensity-matched patient level comparison of the TAXUS Liberte and TAXUS Element (ION) paclitaxel-eluting stents:  Does stent platform make a difference? J Am Coll Cardiol 2011;57:E1698.

Smits P, Kedhi E, Kereiakes DJ, Serruys PW, Parise H, Fahy M, Stone G. Stent thrombosis after everolimus-eluting versus paclitaxel-eluting coronary stents: Insights from the SPIRIT II, III, IV and COMPARE pooled database. J Am Coll Cardiol 2011;57:E1764.

Smits P, Kereiakes DJ, Fahy M, Kedhi E, Parise H, Stone G.  Predictors of early, late and very late stent thrombosis from the SPIRIT II, III, IV and COMPARE pooled database. J Am Coll Cardiol 2011;57:E1765.

Kedhi E, Smith PC, Serruys PW, Kereiakes DJ, Parise H, Fahy M, Stone GW.  Everolimus-eluting vs. paclitaxel-eluting stents. Two year results from a patient level pooled analysis from the SPIRIT II, III, IV and COMPARE randomized trials. J Am Coll Cardiol 2011;57:E1824.

Naidu SS, Turco MA, Lane J, Mauri L, Popma JJ, Kereiakes DJ. Differences in 30 day major adverse cardiac events between Cypher and Taxus in contemporary vein graft intervention:  results from the AMEthyst study.  (presented at SCAI 10, Las Vegas 5/06-09/2009; poster B-24)

Teirstein P, Stone GW, Meredith IT, Mann T, Rabinowitz A, Lee TC, Kereiakes DJ, Carrie D, Cannon LA, Allocco DJ, Dawkins KD. The PLATINUM small vessel trial of the novel thin-strut platinum-chromium PROMUS Element everolimus-eluting stent.  EuroPCR2011 (oral presentation 5/20/11; Paris, France)

Chrysant S, Fernandez V, Heyrman R, Izzo J, Kereiakes DJ, Lee J, Littlejohn T, Melino M, Oparil S. Long-term efficacy and safety of combination olmesartan medoxomil/amiodipine besylate + hydrochlorothiazide in patients with hypertension: the TRINITY study. Primary abstract. ISH 2010 (presented 9/30/10; Vancouver, Canada)

Chrysant S, Fernandez V, Heyrman R, Izzo J, Kereiakes DJ, Lee J, Littlejohn T, Melino M, Oparil S. Efficacy of combination olmesartan medoxomil + amiodipine besylate + hydrochlorothiazide in patients with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease:  the TRINITY study. ISH 2010 (presented 9/30/10; Vancouver, Canada)

Chrysant SG, Kereiakes DJ, Oparil S, Izzo J, Littlejohn T III, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoximil/amlodipine besylate+hydrochlorothiazide stratified by age: the TRINITY study subgroup analysis. ESH 2011 (poster presentation 6/20/2011; Milan, Italy).

Chrysant SG, Kereiakes DJ, Izzo J, Littlejohn T III, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoximil/amlodipine besylate+hydrochlorothiazide stratified by race: the TRINITY study subgroup analysis. ESH 2011 (oral presentation 6/20/2011; Milan, Italy).

Oparil S, Izzo J, Chrysant SG, Kereiakes DJ, Littlejohn T III, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoximil/amlodipine besylate+hydrochlorothiazide stratified by diabetic status and body mass index: the TRINITY study. ESH 2011 (oral presentation 6/20/2011; Milan, Italy).

Kereiakes DJ, Chrysant SG, Izzo J, Littlejohn T III, Oparil S,Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoximil/amlodipine besylate+hydrochlorothiazide based on hypertension severity: the TRINITY study. ESH 2011 (oral presentation 6/20/2011; Milan, Italy).

Littlejohn T III, Kereiakes DJ, Chrysant SG, Izzo J, Oparil S,Melino M, Lee J, Fernandez V, Heyrman R. Distribution of systolic blood pressure reductions from the TRINITY study: Efficacy of combination olmesartan medoximil/amlodipine besylate+hydrochlorothiazide. ESH 2011 (oral presentation 6/20/2011; Milan, Italy).

Chrysant S, Kereiakes DJ, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.  Long-term efficacy and safety of combination olmesartan medoxomil (OM)/amlodipine besylate (AML)+Hydrochlorothiazide (HCTZ) in study participants with hypertension based on age: the TRINITY study. ASH 2011 (presented 5/22/11; PO-139).

Chrysant S, Kereiakes DJ, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.  Long-term efficacy and safety of combination olmesartan medoxomil (OM)/amlodipine besylate (AML)+Hydrochlorothiazide (HCTZ) - the TRINITY study: a subgroup analysis by study participant race. ASH 2011 (presented 5/22/11; PO-140).

Oparil S, Izzo J, Chrysant S, Kereiakes DJ, Littlejohn T, Melino M, Lee J, Fernandez V, Heyrman R.  Long-term efficacy and safety of combination olmesartan medoxomil (OM)/amlodipine besylate (AML)+Hydrochlorothiazide (HCTZ) - the TRINITY study: subgroup analyses based on study participant diabetes status and BMI. ASH 2011 (presented 5/22/11; PO-150).

Lansky AJ, Yaqub M, Sood P, Shi-Wa Y, Wang J, Caputo R, Farhat N, Applegate R, Skelding K, Kereiakes DJ, Sudhir K, Stone GW.  Performance of everolimus-eluting and paclitaxel-eluting coronary stents in women: two-year outcomes from the SPIRIT IV trial. CRT 2011 (presented 2/27/11; Washington, DC)

Lansky A, Yaqub M, Hou L, Applegate RJ, Wang JC, Skelding K, Hermiller JB, Kereiakes DJ, Stone GW.  Evaluation of everolimus-eluting and paclitaxel-eluting stents in patients with jailed side branches:  Two-years results from the SPIRIT IV trial.  ESC 2011 (oral presentation 8/31/11; abstract #5240).

Sullivan RM, Murillo J, Gerritse B, Chung ES, Orlov MV, Stegemann B, Fedewa M, Peterson B, Olshansky B. Do baseline diastolic echocardiographic parameters predict outcome after resynchronization therapy? Results from the PROSPECT trial. Scientific Sessions of the Heart Rhythm Society. San Francisco, CA, May 2011.

Stone GW, Yaqub M, Sood P, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Hattori K, Su X, Simonton CA, Lansky AJ, Cutlip DE, Sudhir K, Kereiakes DJ for the SPIRIT IV Investigators.  A large-scale randomized comparison of everolimus-eluting and paclitaxel-eluting stents:  three-year clinical outcomes from the SPIRIT IV trial. TCT 2011; JACC 2011;58:9 TCT-30 (abstract).

Costa MA, Yaqub M, Kereiakes DJ, Smith Jr. RS, Yu X, Aji J, Cannon LA, Wang JC, Simonton C, Sood P, Sudhir K for the SPIRIT PRIME Investigators.  One-year outcomes after implantation of XIENCE PRIME and XIENCE PRIME long lesion stents in patients with coronary artery disease:  primary endpoint results of the SPIRIT PRIME multicenter clinical trial. TCT 2011; JACC 2011;58:11; TCT-38 (abstract).

Kereiakes DJ, Cannon LA, Ormiston JA, Wang H, Underwood P, Dawkins KD.  Two-year outcomes of a propensity-matched comparison of the ION and TAXUS Liberté paclitaxel-eluting stents. TCT 2011; JACC2011;58:64;TCT-237 (abstract/poster)

Cannon LA, Kereiakes DJ, Batchelor W, Deibele A, Hopkins J, Foster RE, Underwood P, Dawkins KD.  Long-term follow-up of the platinum chromium TAXUS Element (ION) stent:  PERSEUS two-year results.  TCT 2011; JACC2011;58:70; TCT-257 (abstract/poster).

Kereiakes DJ, et al.  ELEVATE-TIMI 56:  Escalating clopidogrel by involving a genetic strategy-thrombolysis in myocardial infarction 56. AHA 2011 (Late Breaking Clinical Trial; presented 11/16/11, Orlando, FL).

Ryan TD, Grenier MA, Taylor MD, Cripe LH, Pratt J, King EC, Mazur W, Jefferies JL, Benson DW, Hor KN. Abnormal circumferential strain present in young Duchenne muscular dystrophy patients. Oral presentation at the American Heart Association Annual Scientific Sessions, Orlando, FL, November 12-16, 2011.

Henry-Okafor Q, Collins S, Jenkins C, Miller K, Peng X, Smith H, Maron DJ, Naftilan A, Fermann G, Menon S, Weintraub N, McPherson J, Sawyer DB, Storrow AB. Utility of Neuregulin-1ß in the diagnosis and prognosis of acute heart failure. Poster presentation at ACEP 10/16/11, San Francisco, CA.

Povsic TJ, Vavalle JP, Aberle LH, Zelenkofske SL, Mehran R, Cohen MG, Buller CE, Cornel JH, Kasprzak JD, Montalescot G, Fail P, Sarembock IJ, Alexander JH. Use of the REG1 anticoagulation system during PCI may improve bleeding and iscemic complications compared with heparin: a PCI substudy from the Phase 2B RADAR trial. TCT 2011. J Am Coll Cardiol 2011;58:47-48;TCT-178 (abstract).

2010

Chung ES , Bartone C, Menon S, Mazur W, O’Brien T, Kereiakes DJ. Target weight guided treatment of acute heart failure using ultrafiltration or usual care:  results of a randomized pilot study.  Presentation at 14th Annual Scientific Sessions of The Heart Failure Society of America, San Diego, CA, September 2010.

Kereiakes DJ , Sudhir K, Hermiller JB, Lansky AJ, Doostzadeh J, Pierson W, Su X, Gordon PC, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multi-Vessel Stenting: Pooled Analysis from the SPIRIT III and SPIRIT IV Randomized Trials. J Am Coll Cardiol 2010;55;A140:E1317 (#1195-174).

Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Paris H, Fahy M, Smits PC. Stent thrombosis after everolimus-eluting versus paclitaxel-eluting coronary stents: Insights from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE pooled database. Circ 2010;122:A14593.

Losordo DW, Henry TD, Schatz RA, Lee JS, Costa M, Bass T, Schaer GL, Mendelsohn F, Davidson C, Waksman R, Soukas PA, Simon D, Chronos N, Fortuin FD, Huang PP, Weintraub N, Yeung A, Rosenfield K, Wong SC, Taussig A, Raval AN, Sherman W, Kereiakes DJ, Strumpf RK, Port S, Pieper K, Ewenstein B, Story KO, Barker KB, Harrington RA. Randomized, double-blind, placebo-controlled trial of autologous CD34+ cell therapy for refractory angina:2-year safety analysis. Circ 2010;122:A15621.

Stone GW, Kedhi E, Serruys PW, Paris H, Fahy M, Smits PC, Kereiakes DJ. Are the clinical outcomes with everolimus-eluting versus paclitaxel-eluting coronary stents different in patients with and without diabetes? Insights from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE randomized trials. Circ 2010;122:A17024.

Stone GW, Rizvi A, Newman W, Applegate RJ, Cannon L, Maddux J, Williams J, Sood P, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ.  Is premature thienopyridine discontinuation safe with everolimus-eluting stents? Analysis from the SPIRIT IV trial. Circ 2010;122:A17066.

Kirtane A, Sood P, Applegate RJ, Yaqub M, Onuma Y, Wang JC, Su X, Miquel-Hebert K, Lansky AJ, Kereiakes DJ, Simonton CA, Sudhir K, Serruys PW, Stone GW.  Predictors of stent thrombosis after everolimus-eluting and paclitaxel-eluting stents: the pooled SPIRIT randomized trial experience at two years of follow-up. Circ 2010;122:A17174.

Kereiakes DJ , Cannon L, Applegate RJ, Clark L, Pierson W, Su X, Captuo R, Farhat N, Maddux J, Jonnavithula L, Lanksy AJ, Fink S, Sudhir K, Stone GW.  Predictors of stent thrombosis in the SPIRIT IV randomized trial of everolimus-eluting and paclitaxel-eluting stents. Is there a difference between drug-eluting stents? EuroIntervention 2010;6(H):102.

Stone GW, Yaqub M, Sood P, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Hattori K, Su X, Simonton CA, Lansky AJ, Cutlip DE, Sudhir K, Kereiakes DJ for the SPIRIT IV investigators.  A large-scale randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical outcomes from the SPIRIT IV trial. J Am Coll. Cardiol. 2010;56:B8

Kirtane A, Sood P, Applegate RJ, Yaqub M, Onuma Y, Wang JC, Su X, Miquel-Hebert K, Lansky AJ, Kereiakes DJ, Simonton CA, Sudhir K, Serruys PW, Stone GW.  Predictors of stent thrombosis after everolimus-eluting and paclitaxel-eluting stents:  The pooled SPIRIT II, III, and IV randomized trial experience. J Am Coll. Cardiol. 2010;56:B11

Cannon LA, Kereiakes DJ, Ghali M, Stoler R, Carney R, Caputo R, Yakubov S, Hood KL, Underwood P, Dawkins KD.  The TAXUS Element paclitaxel-eluting stent in patients with and without diabetes:  Twelve-month outcomes of the PERSEUS clinical studies. J Am Coll. Cardiol. 2010;56:B52

Kereiakes DJ , Sachson RA, Qian C, Patel M.  Efficacy and onset of antihypertensive effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and type 2 diabetes. J Clin Hypertens (Greenwich) 2010;12(1):A111-112 (PO-233).

Kereiakes DJ , Pierson W, Sudhir K, Clark L, Rizvi A, Newman W, Mastali K, Wang J, Cao S, Hattori K, Lansky AJ, Fink S, Applegate RJ, Stone GW.  Predictors of clinical outcomes in the SPIRIT IV randomized trial of everolimus-eluting and paclitaxel eluting stents.  EuroIntervention 2010;6(H):114.

Kereiakes DJ , Chrysant SG, Melino M, Fernandez V, Lee J, Heyrman R.  Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) based on severity of hypertension: the TRINITY study. Journal of Clinical Hypertension 2010 April 12(1):A37 (#PO-45).